GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 970 participants.

Also called NCT01813422

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 970 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01813422
  • EudraCT 2012-004208-37
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01813422. Randomized; quadruple masking; primary purpose treatment. Start 2013-04-18 (actual); primary completion 2016-07-12 (actual). Results posted on 2018-01-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Acronym
GLAGOV
Condition
Hypercholesterolemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01813422
Content hash
5f3daeb60bedc849856190749d88f97e1d33fa9de9b64e0ea93ec85eefc089ea